GlycoMimetics
GlycoMimetics
GLYC
NASDAQ
0.18
USD
-35.71%
About
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.
Its drug candidates include Uproleselan, GMI-1687, Galectin Antagonists and GMI-1359. It is developing Uproleselan, a specific E-selectin antagonist, to be used in combination with chemotherapy to treat patients with AML, a life-threatening hematologic cancer, and potentially other hematologic cancers.
It has designed an antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. GMI-1359 is a drug candidate that simultaneously targets both E-selectin and a chemokine receptor (CXCR4)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.5M |
| Three Month Average Volume | 80.5M |
| High Low | |
| Fifty-Two Week High | 3.5299 USD |
| Fifty-Two Week Low | 0.16 USD |
| Fifty-Two Week High Date | 23 Jan 2024 |
| Fifty-Two Week Low Date | 28 Aug 2024 |
| Price and Volume | |
| Current Price | 0.1763 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | -17.79% |
| Thirteen Week Relative Price Change | -39.22% |
| Twenty-Six Week Relative Price Change | -94.67% |
| Fifty-Two Week Relative Price Change | -91.21% |
| Year-to-Date Relative Price Change | -93.69% |
| Price Change | |
| One Day Price Change | 1.79% |
| Thirteen Week Price Change | -34.94% |
| Twenty-Six Week Price Change | -94.14% |
| Five Day Price Change | -7.21% |
| Fifty-Two Week Price Change | -88.98% |
| Year-to-Date Price Change | -92.53% |
| Month-to-Date Price Change | -18.76% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.59655 USD |
| Book Value Per Share (Most Recent Quarter) | 0.31112 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.59655 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.31112 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.63308 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00016 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00016 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.58254 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.60713 USD |
| Normalized (Last Fiscal Year) | -0.58254 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.58254 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.60713 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.58254 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.60713 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.64902 USD |
| Cash Per Share (Most Recent Quarter) | 0.34716 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.58012 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.6057 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.55446 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -2,020 |
| Cash Flow Revenue (Trailing Twelve Months) | -357,190 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -391,132.40% |
| Pretax Margin (Last Fiscal Year) | -368,994.20% |
| Pretax Margin (5 Year) | -2,243.52% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -392,752.90% |
| Operating Margin (Trailing Twelve Months) | -408,770.50% |
| Operating Margin (5 Year) | -2,305.67% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -368,994.20% |
| Net Profit Margin (Trailing Twelve Months) | -391,132.40% |
| Net Profit Margin (5 Year) | -2,243.52% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -33.99% |
| Tangible Book Value (5 Year) | -28.49% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -90.05% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -29.82% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -21.85% |
| EPS Change (Trailing Twelve Months) | 7.47% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -22,386,050 |
| Net Debt (Last Fiscal Year) | -41,792,830 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1.1K |
| Price to Sales (Trailing Twelve Months) | 1.1K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -34,901,290 |
| Free Cash Flow (Trailing Twelve Months) | -35,719,020 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -75.98% |
| Return on Assets (Trailing Twelve Months) | -90.71% |
| Return on Assets (5 Year) | -43.60% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -90.72% |
| Return on Equity (Trailing Twelve Months) | -104.49% |
| Return on Equity (5 Year) | -48.39% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -90.65% |
| Return on Investment (Trailing Twelve Months) | -103.87% |
| Return on Investment (5 Year) | -47.82% |